---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-023921"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2021-11-22T23:59:59+00:00"
generated_at: "2026-06-28T05:59:23.175437+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director Joseph Zakrzewski resigns from Sangamo Board effective March 1, 2022

## Summary
- Joseph S. Zakrzewski voluntarily resigned from the Board, effective March 1, 2022.
- Resignation not due to any disagreement with the Company on operations, policies, or practices.
- No replacement announced; Board size and composition will adjust upon his departure.

## SEC filing metadata
- accession: 0001628280-21-023921
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2021-11-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828021023921/0001628280-21-023921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828021023921/sgmo-20211117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-023921
- JSON: https://secwatch.observer/filing/0001628280-21-023921.json
- Plain text: https://secwatch.observer/filing/0001628280-21-023921.txt

## Key facts
- Executive change
  Joseph S. Zakrzewski resigned as Director at SANGAMO THERAPEUTICS, INC.
  - Action: resigned
  - Role: Director
  source text: On November 17, 2021, Joseph S. Zakrzewski, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his voluntary resignation from the Board effective March 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828021023921/0001628280-21-023921-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.